Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
105 Results for "
Histone Acetyltransferase
" in MedChemExpress (MCE) Product Catalog:
Products (105)
105 Results for "Histone Acetyltransferase" in MCE Product Catalog:
135
135 Publications Verification
Synonyms: Diferuloylmethane; Natural Yellow 3; Turmeric yellow
110
110 Cited Publications
Research Areas:
A-485, a chemical probe, is a potent and selective catalytic inhibitor of p300/CBP with IC50s of 9.8 nM and 2.6 nM for p300 and CBP histone acetyltransferase (HAT), respectively .
97
97 Cited Publications
Research Areas:
C646 is a selective and competitive histone acetyltransferase p300 inhibitor with Ki of 400 nM, and is less potent for other acetyltransferases .
17
17 Cited Publications
Cat. No.: HY-N2020
CAS No.: 16611-84-0
Synonyms: Hydroginkgolic acid; Ginkgolic Acid C15:0
13
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Butyrolactone 3 (MB-3) is a specifical small-molecule inhibitor of the histone acetyltransferase Gcn5 (IC50=100 μM), which has a high affinity to the Gcn5 enzyme comparable to that of its natural substrate, histone H3. Butyrolactone 3 shows weak inhibitory on CBP (IC50=0.5 mM). Butyrolactone 3 can be used in studies of cancer, metabolic, autoimmune and neurological diseases .
13
13 Cited Publications
Target:
Research Areas:
CTB is a potent p300 histone acetyltransferase activator . CTB can effectively induce apoptosis in MCF-7 cells .
13
13 Cited Publications
Research Areas:
α-NETA is a potent and noncompetitive choline acetyltransferase (ChA) inhibitor with an IC50 of 9 μM. α-NETA is a potent ALDH1A1 (IC50=0.04 µM) and chemokine-like receptor-1 (CMKLR1) antagonist. α-NETA weakly inhibits cholinesterase (ChE; IC50=84 µM) and acetylcholinesterase (AChE; IC50=300 µM). α-NETA has anti-cancer activity .
7
7 Cited Publications
Target:
Research Areas:
NU9056 is a potent and selective Tip60 (KAT5) histone acetyltransferase inhibitor with an of 2 µM. NU9056 shows >16-fold selectivity for Tip60 over PCAF, p300 and GCN5. NU9056 induces apoptosis of prostate cancer cells .
5
5 Cited Publications
4
4 Cited Publications
Target:
Research Areas:
WM-8014 is an inhibitor of MOZ, a member of histone acetyltransferases, with an IC50 of 55 nM.
4
4 Cited Publications
Target:
Research Areas:
PU139 is a potent pan-histone acetyltransferase (HAT) inhibitor. PU139 blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB (cAMP response element-binding) protein (CBP) and p300 with IC50s of 8.39, 9.74, 2.49 and 5.35 μM, respectively .
3
3 Cited Publications
Cat. No.: HY-W015239
CAS No.: 605-62-9
Target:
Research Areas:
KAT8-IN-1 is a lysine (K) acetyltransferase 8 (KAT8) inhibitor, with IC50s of 141 μM (KAT8), 221 μM (KAT2B), 106 μM (KAT3B), respectively. KAT8 inhibits histone acetyltransferases (HATs), and could result in disease states, such as cancer or inflammatory diseases .
3
3 Cited Publications
Target:
Research Areas:
TH1834 is a specific Tip60 (KAT5) histone acetyltransferase (HAT) inhibitor. TH1834 induces apoptosis and increases DNA damage in breast cancer. TH1834 does not affect the activity of related histone acetyltransferase MOF. Anticancer activity .
3
3 Cited Publications
Target:
Research Areas:
TH1834 dihydrochloride is a specific Tip60 (KAT5) histone acetyltransferase inhibitor. TH1834 dihydrochloride induces apoptosis and increases DNA damage in breast cancer. TH1834 dihydrochloride does not affect the activity of related histone acetyltransferase MOF. Anticancer activity .
2
2 Cited Publications
Cat. No.: HY-W013274
CAS No.: 357649-93-5
Target:
Research Areas:
CPTH2 is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B) .
2
2 Cited Publications
Synonyms: Diferuloylmethane (Standard); Natural Yellow 3 (Standard); Turmeric yellow (Standard)
2
2 Cited Publications
Target:
Research Areas:
JG-2016 is a potent inhibitor of histone acetyltransferase 1 (HAT1) with an IC50 of 14.8 μM. JG-2016 can inhibit the growth of multiple tumor cells and has anti-tumor activity .
2
2 Cited Publications
Cat. No.: HY-16531
CAS No.: 1311423-89-8
Target:
Research Areas:
YF-2 is a highly selective, blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC50s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer's disease .
2
2 Cited Publications
Cat. No.: HY-16531A
CAS No.: 1312005-62-1
Target:
Research Areas:
YF-2 hydrochloride is a highly selective, blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC50s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer's disease .
2
2 Cited Publications
Cat. No.: HY-P701625
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: KAT8; Protein Acetyltransferase KAT8; Prev. MYST1; FLJ14040; HMOF; ZC2HC8; MOF; MYST-1; Males-Absent On The First Protein Homolog; Ortholog Of Drosophila Males Absent On The First (MOF); MOZ, YBF2/SAS3, SAS2 And TIP60 Protein 1; Probable Histone Acetyltra
Species:
Human
Source:
E. coli
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
